Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation
Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.
The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the gold standard therapy, with other drug classes including dopamine agonists and Monoamine Oxidase B (MAO-B) inhibitors also used to treat early and advanced cases. With no current treatment showing effectiveness in delaying the course of the disease, PD remains incurable. The high unmet need for a disease-modifying therapy is reflected in the pipeline, where a high proportion of early-stage first-in-class programs target the potential pathogenic mechanisms underlying neurodegeneration.
PD is a crowded market with many neuromodulatory drug classes available. However, a disease-modifying therapy with neuroprotective effects is yet to be developed. - What are the primary mechanisms that are thought to contribute to neuronal death? - What are the major barriers facing the development of investigational neuroprotective candidates? Analysis reveals a high level of innovation and diversity in the pipeline, with 121 first-in-class programs acting on 57 unique molecular targets. Neuromodulatory targets remain the dominant target family, particularly in the late-stage pipeline. - What are the first-in-class families with a significant presence? - How well do they align with the underlying pathways governing neuronal death in PD? Some of the first-in-class targets have a potentially stronger chance of being translated into novel treatments for PD. - What is the scientific rationale behind these targets? How do they perform in Preclinical studies? - What are the commonly used disease models and the parameters measuring neuroprotective effects in PD animal studies? Deals involving first-in-class PD products are more likely to be made in earlier stages of development than non-first-in-class deals. - What is the dominant molecular target in the PD deals landscape? - What are the promising first-in-class products still available for future licensing?
Reasons to buy
This report will allow you to - - Understand the current clinical and commercial landscape by considering the proposed pathogenic processes underlying PD neurodegeneration, diagnosis, prognosis, and the available treatment options and their usage in early and advanced PD. - Visualize the composition of the PD market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities. - Analyze the PD pipeline and stratify by stage of development, molecule type, and molecular target - the diversity of molecular targets in the pipeline is extremely encouraging due to the multifaceted nature of PD. - Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential. - Target the most promising and innovative PD products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.
Our reports have been used by over 10K customers, including:
251 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Mental Illness Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
Orexin Receptor Type 2 - Drugs In Development, 2021 Summary According to the recently published report ’Orexin Receptor Type 2 - Drugs In Development, 2021’; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately...
Scope of the Report The report titled “Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)”, provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic...
Narcolepsy - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive...
Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2020 Summary According to the recently published report ’Metabotropic Glutamate Receptor 5 – Pipeline Review, H1 2020’; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes....
Narcolepsy - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.